Company / Operating Margin
Allogene Therapeutics, Inc. Operating Margin History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-344986.3%
FY2024
5-year range
-344986.3% / -157.9%
FY2022-FY2024
Trend
-218328.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin changed -218329% YoY in FY2024, a notable deviation from the 2-year average annual change of -109114%.
Based on SEC 10-K filings.
-344986.3% in FY2024.
Declined from -152068.0% to -344986.3% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, operating margin decreased 218328.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -344986.3% | -218328.7% |
| FY2023 | -157.9% | +99.9% |
| FY2022 | -152068.0% | - |
| FY2021 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026